ContractWarrant Agreement • November 6th, 2013 • Concert Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUED UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THIS WARRANT MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF THIS WARRANT.
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • November 6th, 2013 • Concert Pharmaceuticals, Inc. • Pharmaceutical preparations
This DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is entered into as of February 26, 2013 (the “Effective Date”) by and between CONCERT PHARMACEUTICALS, INC., a Delaware corporation, with its principal place of business at 99 Hayden Avenue, Suite 500, Lexington, MA 02421, USA (“Concert”), and JAZZ PHARMACEUTICALS IRELAND LIMITED, an Irish company, with its principal place of business at Fourth Floor, Connaught House, One Burlington Road, Dublin 4, Ireland (“Jazz”). Concert and Jazz are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CONCERT PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under Amended and Restated 2006 Stock Option and Grant PlanConcert Pharmaceuticals, Inc. • November 6th, 2013 • Pharmaceutical preparations
DEVELOPMENT AND LICENSE AGREEMENT BETWEEN CONCERT PHARMACEUTICALS, INC. AND AVANIR PHARMACEUTICALS, INC. FOR DEUTERATED DEXTROMETHORPHAN PRODUCTS DATED AS OF FEBRUARY 24, 2012Development and License Agreement • November 6th, 2013 • Concert Pharmaceuticals, Inc. • Pharmaceutical preparations
This Development and License Agreement (“Agreement”) dated as of this 28th of February, 2012 (“Effective Date”), is between Concert Pharmaceuticals, Inc., a Delaware corporation having offices located at 99 Hayden Avenue, Suite 500, Lexington, Massachusetts 02421, USA (“Concert”) and Avanir Pharmaceuticals, Inc., a Delaware corporation having offices located at 20 Enterprise, Suite 200, Aliso Viejo, California 92656, USA (“Avanir”). Each of Concert and Avanir may be referred to hereinafter individually as a “Party” and together as the “Parties.”
VIA HAND DELIVERY (Delivered as amended via electronic mail) October 2, 2013 (as amended October 8, 2013, October 14, 2013, and October 17, 2013) James E. ShipleyConcert Pharmaceuticals, Inc. • November 6th, 2013 • Pharmaceutical preparations • Massachusetts
THIRD AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 6th, 2013 • Concert Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Third Amended and Restated Registration Rights Agreement (this “Agreement”) is entered into as of June 1, 2009 by and among Concert Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and the persons and entities listed on signature pages hereto (the “Investors”) and amends and restates the Second Amended and Restated Registration Rights Agreement (the “Original Agreement”) dated as of April 25, 2008 by and among the Corporation and the persons and entities listed on the signature pages thereto (the “Prior Investors”).
